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Abstract
Background: Malaria caused by Plasmodium vivax is an experimentally neglected severe disease with a substantial
burden on human health. Because of technical limitations, little is known about the biology of this important
human pathogen. Whole genome analysis methods on patient-derived material are thus likely to have a substantial
impact on our understanding of P. vivax pathogenesis and epidemiology. For example, it will allow study of the
evolution and population biology of the parasite, allow parasite transmission patterns to be characterized, and may
facilitate the identification of new drug resistance genes. Because parasitemias are typically low and the parasite
cannot be readily cultured, on-site leukocyte depletion of blood samples is typically needed to remove human DNA
that may be 1000X more abundant than parasite DNA. These features have precluded the analysis of archived
blood samples and require the presence of laboratories in close proximity to the collection of field samples for
optimal pre-cryopreservation sample preparation.
Results: Here we show that in-solution hybridization capture can be used to extract P. vivax DNA from human
contaminating DNA in the laboratory without the need for on-site leukocyte filtration. Using a whole genome
capture method, we were able to enrich P. vivax DNA from bulk genomic DNA from less than 0.5% to a median of
55% (range 20%-80%). This level of enrichment allows for efficient analysis of the samples by whole genome
sequencing and does not introduce any gross biases into the data. With this method, we obtained greater than 5X
coverage across 93% of the P. vivax genome for four P. vivax strains from Iquitos, Peru, which is similar to our results
using leukocyte filtration (greater than 5X coverage across 96% of the genome).
Conclusion: The whole genome capture technique will enable more efficient whole genome analysis of P. vivax
from a larger geographic region and from valuable archived sample collections.
Keywords: Malaria
Background
The global burden of Plasmodium vivax is being in-
creasingly reevaluated as more fatal cases are identified
and drug resistant strains are discovered [1,2]. Despite
the fact that 2.85 billion people live in P. vivax endemic
areas, there is a substantial lack of knowledge surround-
ing the mechanisms of biological features unique to
P. vivax, constraining the ability to design appropriate
control strategies.
The fact that P. vivax exclusively invades reticulocytes
impairs the development of a reliable, long-term in vitro
culture method, a technique that has been available for
the study of P. falciparum for over 30 years [3]. While
some progress has been made in establishing P. vivax
culture in the laboratory, the lack of a reproducible
in vitro culture method prevents basic laboratory manip-
ulations, such as genetic crosses, and has limited the
types of questions that can be answered about P. vivax
biology.
The advent of low-cost whole genome technologies
allows direct analysis of P. vivax field populations, with-
out the need for in vitro culture. With the completion of
the P. vivax reference genome as well as the publication
of the first P. vivax resequencing project [4], single
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nucleotide variants (SNV) are now being identified that
can be used to track parasite populations and investigate
parasite population structure on both the regional and
global levels. In addition, new whole genome sequencing
technologies allow for sequencing hundreds of samples
from different geographic locations and thus take advan-
tage of the thousands of natural genetic crosses that
occur over time and in the context of parasite move-
ments among regions under different epidemiological
contexts (reverse genetics). Using signatures in the gen-
ome left by these natural crosses, investigators will be
able to identify regions of the genome under selection
and, potentially, the genes involved in P. vivax virulence,
drug resistance, and immune evasion.
A critical barrier to the whole genome analysis of
P. vivax is the ability to obtain sufficient quantities of
high quality parasite genomic DNA free of human nu-
cleic acid contamination. Current protocols for obtain-
ing parasite DNA for whole genome studies from
P. falciparum field isolates consist of culture adapting
the isolated parasites and passaging them for 3–4 weeks.
This intermediate step achieves two things: one, it
expands the parasite population allowing for isolation of
a larger quantity of DNA and, two, it removes human
leukocytes containing contaminating DNA. Since there
is no reliable culture method to propagate P. vivax
in vitro, alternative methods have to be designed to work
with nucleic acids from P. vivax field samples.
To address the two issues of low quantities of parasite
DNA and human DNA contamination, the standard
method adopted by the P. vivax research community is
leukocyte filtration using ion-exchange columns fol-
lowed by whole genome amplification (WGA) [4,5]. This
current method of obtaining P. vivax DNA from field
samples is only feasible when the patient blood samples
are collected in close proximity to a field laboratory be-
cause of the need to filter out the leukocytes before they
lyse. This logistical issue precludes the collection of field
samples from remote areas where P. vivax is endemic
and thus limits our understanding of the population
genetics of P. vivax. In addition, there are many samples
that were collected before leukocyte depletion became a
standard technique. As of now these samples cannot be
analyzed via whole genome sequencing prohibiting the
use of these samples to study how P. vivax has evolved
over time.
Here we demonstrate the feasibility of analyzing P.
vivax field samples without on-site leukocyte filtration
using an in-solution hybridization capture method [6,7].
By modifying the whole genome capture protocol
designed for P. falciparum by Melnikov et al. [8], we
show that Sal1 reference genomic DNA can be used to
create whole genome baits, which can then be used to
extract P. vivax genomic DNA from the contaminating
human DNA in both frozen samples and mock blood
spots. After the whole genome extraction of P. vivax
DNA and subsequent whole genome sequencing, greater
than 90% of the P. vivax assembled genome (~22 million
bases) can be confidently assigned a genotype, or
“called.” Our whole genome sequencing results are
equivalent to previous results obtained using the
leukocyte filtration protocol, and we, therefore, propose
that because of its much easier application in the field,
whole genome capture is a superior method of analyzing
large numbers of P. vivax field samples from diverse
geographic areas.
Results
Synthesis of whole genome baits
We created whole genome baits (WGB) using in vitro
transcription with Sal1 genomic DNA as the template.
Briefly, Sal1 genomic DNA was fragmented to an aver-
age of 200 bp and a T7 promoter sequence was ligated
onto the fragment ends. In vitro transcription was then
conducted in the presence of biotinylated dUTP, creating
biotinylated RNA baits. The WGB were initially tested
on two mock Sal1 infections: one created by combining
1% Sal1 DNA with 99% human DNA and a second cre-
ated by combining 0.1% Sal1 DNA and 99.9% human
DNA. The baits were able to enrich these mock samples
from 1% P. vivax DNA to 86% P. vivax DNA and from
0.1% P. vivax DNA to 44% P. vivax DNA (Figure 1).
Additional WGB can be created through subsequent
in vitro transcription reactions.
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Figure 1 Enrichment of Sal1 DNA using whole genome baits.
Mock P. vivax infections were created by combining Sal1 reference
DNA and human DNA. These samples were then whole genome
captured using the Sal1 derived baits. Pre and Post bars refer to the
percent P. vivax DNA in the mock sample before and after whole
genome capture.
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Whole genome capture and sequencing of P. vivax-
field samples
We performed a whole genome capture protocol (see
Methods) on five field samples (SA-94, SA-95, SA-96,
SA-97, SA-98) collected in Iquitos, Peru during the 2010
transmission season using the WGB derived from Sal1
genomic DNA. Patient blood samples were centrifuged
after collection with the serum and Buffy coat subsequently
removed. Erythrocytes were then frozen at −80 °C and
shipped back to the United States for further analysis. For
three samples (SA-96, SA-97, SA-98), DNA was isolated
from the frozen red blood cell pellet. The parasitemias for
these three samples were within the expected range for
P. vivax infection, which is substantially lower than P. fal-
ciparum infection (Table 1). In order to assess the propor-
tion of P. vivax DNA in our starting material we analyzed
the bulk genomic DNA using qPCR. The percent of
P. vivax DNA present after enrichment with whole gen-
ome capture was determined by whole genome sequencing
(see below) (Table 1). For the remaining two samples
(SA-94 and SA-95), 125 ul of erythrocytes were placed on
Whatman FTA nucleic acid filter paper, stored for 2 weeks
at room temperature to create mock blood spots, and then
DNA was isolated using a standard extraction protocol.
Genomic DNA recovered after whole genome capture
was sequenced using the Illumina HiSeq 2000 platform
and 4.7 - 6.3 billion bases of data were obtained per
sample. The sequencing reads were then aligned to the
Sal1 reference using BWA [9], and sequencing and align-
ment characteristics were generated using Picard and the
Genome Analysis Toolkit (GATK) [10]. We compared the
sequencing statistics from the whole genome captured
samples to the genome sequence of IQ07. This strain from
Iquitos, Peru was collected in the 2007 transmission sea-
son and had previously been prepared by leukocyte filtra-
tion and sequenced by our lab [4]. Since IQ07 is the only
published sequencing data for a P. vivax sample taken dir-
ectly from a patient, we considered the sequencing ana-
lysis of the IQ07 strain as our positive control. We also
obtained sequencing data for Acre3, a P. vivax strain col-
lected in Acre, Brazil, which had been neither leukocyte
filtered nor enriched using whole genome capture. Acre3
served as our negative control.
After aligning the sequencing reads, PCR duplicates,
which arise during the final PCR amplification step of
both library preparation methods, were marked to re-
duce false coverage. We identified PCR duplicates by
finding those sequencing pairs that aligned to the exact
same location in the genome and had the same insert
size. The percentage of PCR duplicates ranged from
12.1% to 46.2% and was higher than the percentage of
PCR duplicates identified in IQ07 (1.86%) or Acre3
(4.38%) (Table 2). The percentage of PCR duplicates was
in line with the percentage of PCR duplicates seen in
Table 1 P. vivax genomic DNA yield from whole blood samples using whole-genome capture
Isolate Parasitemia % P. vivax gDNA
Parasites/μl blood Parasites/RBC (%) Bulk DNA yield (μg) Pre-WGC Post-WGC Fold enrichment
SA-96 2,300 0.04% 3.2 0.53% 52.89% 99.8
SA-97 2,800 0.05% 7 1.34% 60.52% 45.2
SA-98 8,700 0.16% 7.6 3.95% 78.40% 19.8
SA-94 6,100 0.11% 2.4 na 80.13% na
SA-95 1,800 0.03% 1.7 na 20.25% na
IQ07a na na na 41.87% na na
Acre3b na na na 1.42% na na
Abbreviations: RBC, red blood cells; WGC, whole-genome capture; na, not available.
apositive control - leukocyte filtered, bnegative control.
Table 2 Sequencing statistics for whole-genome capture samples
Number of bases
sequenced (billion)
% PCR
duplicates
% genome covered by
5 or more readsIsolate % P. vivax gDNA Coverage (X)
IQ07a 2.3 41.87% 1.86% 35.16 95.33%
Acre3b 1.4 1.42% 4.38% 0.77 0.80%
SA-94c 6.0 80.13% 13.60% 150.31 97.21%
SA-95c 5.3 20.25% 46.17% 21.89 84.73%
SA-96c 4.7 52.89% 32.29% 63.11 93.35%
SA-97c 5.2 60.52% 26.37% 86.75 94.37%
SA-98c 6.3 78.40% 12.14% 160.44 96.51%
apositive control - leukocyte filtered, bnegative control, cwhole-genome capture.
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exome capture studies [11]. After identifying PCR dupli-
cates, sequencing reads from each sample were locally
realigned around indels and areas of high entropy, and
all base quality scores were then recalibrated based on
empiric sample-reference mismatch data.
Following clean up of the aligned reads, we compared
the percent of reads that aligned to the P. vivax refer-
ence from the whole genome capture samples to the
controls. Of the 57.9 million sequencing reads obtained
for IQ07, 42% of the reads aligned to the Sal1 reference
(Table 2). For Acre3, the negative control, only 1.42% of
the 23.5 million sequencing reads aligned to the Sal1
reference. In contrast to the P. vivax field samples ana-
lyzed here, >90% of reads obtained from sequencing la-
boratory reared P. falciparum (with no human
contaminating DNA) align to the P. falciparum
reference.
For the whole genome capture samples the percentage
of reads that mapped to the Sal1 reference ranged from
20% to 80% with 4 out of 5 samples analyzed having a
higher percentage of P. vivax DNA than in IQ07 and all
samples showing a much higher percentage of P. vivax
DNA than Acre3 (Table 2). In addition, the percentage
of reads that aligned to the Sal1 reference was directly
related to the parasites per ul present in the original pa-
tient sample and thus the variance in the whole genome
capture result for both frozen samples and mock blood
spots is a function of the starting parasite gDNA load
(Table 1). Future studies using the whole genome cap-
ture protocol would benefit from prioritizing samples for
sequencing based upon the patients parasitemia at time
of sample collection to limit non-specific binding during
the capture protocol.
Whole genome and chromosome coverage analysis of
whole genome capture samples
After identifying all the reads that mapped to the P. vivax
reference genome, we filtered out low quality reads (map-
ping quality (MQ)< 29) and low quality bases (base qual-
ity (BaseQ)< 20) from those reads that aligned. Both MQ
and BaseQ are Phred scaled scores indicating, respectively,
the accuracy of the alignment as given by BWA and the
accuracy of the base call as determined by the empiric
sample-reference mismatch rate taking into account
known variants. These filtration steps are necessary to en-
sure that machine errors and alignment errors do not bias
the conclusions drawn from the data and the resulting set
of high quality bases was used for all subsequent down-
stream analysis discussed below.
First, genome wide sequencing coverage was com-
puted from the set of high quality aligned bases for all
whole genome capture samples and was compared with
the IQ07 positive control and the Acre3 negative con-
trol. IQ07 was sequenced to a genome wide depth of
34.16X. Genome wide coverage by high quality bases for
the captured samples ranged from 21.89X to 160.44X
and was positively correlated to the percent of the reads
that mapped to the P. vivax reference (Table 2). In
addition, the percentage of the genome covered by dif-
ferent sequencing depths (5X, 10X, etc.) was directly
correlated to the genome wide coverage achieved and is
presented for all whole genome captured samples along
with the positive (shaded area) and negative (orange
line) controls (Figure 2A).
Next we evaluated the number of bases that were
“callable,” i.e. able to have a confident genotype assigned
to them. We defined “callable” for this haploid organism
as being covered by five or more bases all of which have
a BaseQ of 20 or above (99% accurate). Using this cutoff
we predict one incorrectly called genotype in 10 billion
genotype calls or one incorrect genotype call in approxi-
mately 454 malaria genomes analyzed by sequencing. In
the IQ07 strain 95.3% of the entire genome was callable
and in the Acre3 negative control only 0.80% of bases
were callable. Of the five genome captured samples,
greater than 90% of all bases were able to be called in
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Figure 2 P. vivax genomic coverage after whole genome
capture. (A) Percent of the P. vivax genome covered by various
coverage thresholds for the five whole genome capture samples,
the IQ07 positive control (shaded region), and the Acre3 negative
control (orange). (B) The percent of each chromosome that was able
to be confidently genotyped, i.e. callable, for the whole genome
captured samples compared to the IQ07 positive control (upper
scale). The Acre3 negative control is presented on the lower scale.
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four of the samples with the worst performing fifth sam-
ple, SA-95, still having 84.73% of the genome callable.
While genome wide the percentage of callable bases
was high, we next looked at the percentage of callable
bases on the individual chromosome level in order to
identify gross biases in the capture technique (Figure 2B).
Again we used sequencing data from IQ07 as the stand-
ard. All samples prepared by whole genome capture
exhibited the same trend of percentage of callable bases
per chromosome as IQ07, but a slight overall bias to cer-
tain areas of the genome was identified requiring more
sequencing to analyze these regions.
%GC content accounts for the sequencing bias between
the two techniques
We next examined those regions of the genome that
performed poorly in the whole genome capture tech-
nique as compared to the leukocyte filtration protocol.
The bias identified is correlated directly with %GC. The
mean %GC of P. vivax is 45% and both the leukocyte fil-
tration method and the whole genome capture protocol
are able to efficiently sequence regions of mean %GC
content (Additional file 1: Figure S1 and Figure S2 (A)).
In addition, both sequence preparation methods are
poor at sequencing areas of substantially lower %GC
(< 30%).
Where the two methods diverge is sequencing regions
of higher %GC (>50%). The capture method is only ap-
proximately half as efficient at sequencing these regions
as the leukocyte filtration method (Additional file 1:
Figure S1 and Figure S2 (B)). This effect is seen across
all 14 chromosomes and the differential bias is seen
most prominently around the centromere on account of
these regions containing a higher %GC on average than
the whole genome.
Aside from %GC, the bias seen in the capture samples
does not correlate with any other genomic feature in-
cluding SNVs, chromosomal location (except the centro-
mere because of the higher %GC), particular gene
families, or gene rich/poor regions.
Quantity of sequencing data required for P. vivax
resequencing projects
We next investigated the amount of sequencing data
from either the traditional library preparation or the
whole genome capture protocol needed to call a certain
percentage of the genome. Using the data from SA-94,
for which we had initially obtained 150X genome wide
coverage, we randomly downsampled the original data
set to obtain downsampled data sets from 5X to 50X
genome wide coverage at 5X intervals. Only properly
mapped read pairs were included in this analysis and the
reads from a pair were either both chosen or both
excluded. The same downsampling strategy was used on
IQ07 to obtain downsampled data sets from 5X to 30X
coverage at 5X intervals. We also analyzed the full 34X
IQ07 dataset.
At 20X genome wide coverage, 82.52% of the SA-94
genome is covered by five or more reads and therefore
callable (Figure 3). At the same genome wide coverage,
91.8% of the IQ07 genome is callable. This difference in
callable genome percentage at the same level of genome
wide coverage indicates that certain areas of the genome
are more efficiently captured than others leading to un-
even coverage across the genome. As explained above
the regions that are underrepresented in sequencing li-
braries prepared using whole genome capture are those
areas with high %GC. This effect is slight but reprodu-
cible with all of our whole genome capture samples. As
the genome wide coverage increases the discrepancy in
callable bases between the two library preparation meth-
ods decreases. At 30X genome wide coverage, 87.96% of
the SA-94 genome is callable compared to 94.6% of the
IQ07 genome.
While regions of higher %GC are underrepresented in
sequencing libraries created using the whole genome
capture method, they are not absent. Therefore sequen-
cing those samples prepared by whole genome capture
to a higher genome wide coverage than is necessary for
samples prepared by leukocyte depletion will overcome
this bias and allow genotyping of the vast majority of the
genome. We therefore recommend for whole genome
deep sequencing of P. vivax, enough data, taking into ac-
count residual contaminating human DNA, should be
obtained to achieve 30X-35X coverage of the parasite
genome for samples prepared by leukocyte filtration and
50X coverage for samples prepared using the whole gen-
ome capture method. For low-pass SNP discovery se-
quencing, 10X-15X coverage will allow genotyping of a
minimum of 65% of the parasite genome using either
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Figure 3 Confidently genotyped loci at various sequencing
depths. SA-94 (black) and IQ07 (gray) were randomly downsampled
and the mean percent of the genome that is callable of 5 randomly
produced data sets for each coverage threshold is presented.
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the standard library preparation method or the whole
genome capture protocol (Figure 3).
SNVs identified in whole genome captured samples
To further evaluate the quality of data that was pro-
duced from the whole genome capture method, we next
called SNVs from the five whole genome capture sam-
ples and compared them to the SNVs previously identi-
fied in IQ07 (Table 3). SNVs identified here will be
validated and explored in more depth in a future follow-
on paper and the validated SNVs will of course be a pro-
portion of those called here using a purely algorithmic
approach. We show SNV data here to demonstrate that
the whole genome capture method does not produce
data with a substantially different number of high confi-
dence algorithmically identified SNVs as compared to
IQ07 suggesting that the sequencing data obtained is of
high quality.
The total number of SNVs identified in each of the
whole genome capture samples (range 16,596 – 18,916)
was in concordance with the 16,861 SNVs identified in
IQ07. The whole genome capture method performed ei-
ther on frozen whole blood or mock blood spots did not
produce an abnormally high or low number of SNVs in-
dicating that the data was of high quality and in line
with the data produced by the leukocyte filtration proto-
col. In total 32,374 SNVs were identified across all five
genome capture samples including 98% of the SNVs
identified in IQ07.
Next, we analyzed where in the P. vivax genome the
high confidence SNVs were located. P. vivax contains a
number of highly variable gene families including the
merozoite surface protein (msp) family and the serine-
rich antigen (sera) family. These gene families are known
from P. falciparum to be highly variable and initial
P. vivax resequencing studies have demonstrated a high
mutation rate in P. vivax as well [4]. In agreement with
our previous studies, we find that those gene families
predicted to be highly variable do in fact contain high
numbers of SNVs per gene in our whole genome capture
samples (Table 3). In contrast, annotated metabolic
genes have a very low SNV per gene rate, as would be
expected of these housekeeping genes.
In addition to being more or less variable, the magni-
tude of the rate of variability of the gene families ana-
lyzed was consistent across all five genome capture
samples and the IQ07 positive control. The rate of both
synonymous and non-synonymous mutations per gene
in the msp, sera, and metabolic gene families was found
to be a function of the inherent genes in the family and
was not affected by the method of sequencing. This re-
sult further suggests that the whole genome capture
method is unbiased and produces high quality sequen-
cing data that can be used for downstream analysis.
Discussion
Overall the whole genome capture method provides suf-
ficient data with minimal bias to assign a genotype to
greater than 90% of the P. vivax genome. Also, the total
number of SNVs as well as the SNV rates of gene fam-
ilies was consistent across all five genome capture sam-
ples and was in agreement with previous data from
IQ07. Using these metrics the whole genome capture
technique is as efficient as the current leukocyte filtra-
tion method in removing contaminating human gen-
omic DNA and allowing whole genome analysis of
P. vivax field samples without introducing any bias into
the data.
The critical contribution of this method is to be able
to carry out comprehensive whole genome sequencing
on P. vivax samples where human leukocyte removal
has not been or cannot feasibly be done (archival sam-
ples or remote sites). In addition, the whole genome cap-
ture protocol can be performed on starting bulk gDNA
quantities as low as 1 ug. Such analysis will provide new
approaches to investigate P. vivax population biology
with direct applicability to vaccine and drug
development.
The cost of sequencing a leukocyte depleted sample
and a whole genome capture sample are approximately
Table 3 SNVs identifiedby whole genome sequencing
Isolate SNVs MSP7 gene family All MSP gene families SERA gene family Metabolic genes
Syn Non-syn Syn Non-syn Syn Non-syn Syn Non-syn
IQ07a 16,861 1.82 1.64 2.7 4.1 7.07 5.54 0.45 0.6
Acre3b 0 na na na na na na na na
SA-94 17,871 1.93 1.57 3.2 4.41 6.94 5.6 0.37 0.59
SA-95 18,916 2.03 1.77 2.48 4.1 7.3 5.03 0.35 0.64
SA-96 17,946 1.79 1.81 3.23 4.21 6.64 5.61 0.54 0.7
SA-97 18,321 1.86 1.34 2.81 4.19 7.23 5.91 0.44 0.68
SA-98 16,596 1.55 1.28 2.89 3.98 6.94 5.04 0.49 0.68
Abbreviations: SNV, single nucleotide variant; Syn, synonymous; Non-syn, non-synonymous; na, not available.
apositive control - leukocyte filtered, bnegative control.
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the same as both methods lead to a mean P. vivax DNA
percentage of 40%, but the whole genome capture tech-
nique increases the cost of library preparation by 100
USD as compared to the leukocyte filtration process.
Whole genome capture, though, drastically reduces the
time, cost, and effort in the field needed to collect sam-
ples because leukocyte filtration requires getting materi-
als and experienced scientists into the field to actually
perform the procedure thereby limiting the collection of
samples to only certain geographic areas.
Both preparation methods are far superior relative to
sequencing extraneous human DNA from a non-
leukocyte filtered, non-captured sample. In order to se-
quence P. vivax directly from patient whole blood, 80–
100 GB of raw sequencing data would be needed to
achieve the desired depth for confident analysis. While
sequencing costs continue to come down, at this time it
is inefficient to sequence P. vivax without using either
whole genome capture or leukocyte filtration.
Here we have also estimated, for the first time, the
depth of P. vivax sequencing that is necessary for rese-
quencing projects. Our data suggest that analyses aimed
predominantly at P. vivax strain genotyping should col-
lect 30-35X genome-wide coverage, after taking into ac-
count contaminating human DNA, for samples prepared
by leukocyte filtration and 50X genome-wide coverage
for samples prepared by whole genome capture. The
marginal benefit of deeper sequencing weighted against
cost and throughput efficiency does not support add-
itional sequencing beyond these coverage depths for
resequencing studies.
The whole genome capture method is much more
amenable to the collection of parasite samples in the
field since it can be performed on frozen blood samples
or blood spots without the need for complicated labora-
tory manipulations at the site of collection. Whole gen-
ome capture is therefore ideal for analyzing samples
collected in resource poor areas such as remote health
clinics. Analyzing samples from these areas will greatly
expand the knowledge of P. vivax population genetics at
the local level as well as allow for the tracking of parasite
populations.
In addition, whole genome capture is the only way to
analyze archival samples that were not previously
leukocyte filtered before being frozen. Many samples
exist around the world that have unique phenotypes but
up to this point have only been analyzed using sparse
microsatellite markers. The technique presented here
allows for more thorough analysis of these samples that
to this point would have been cost prohibitive.
Conclusion
Taken together, the amount of high quality data (over
90% of the genome covered by 5 or more bases) and the
expanded range of the whole genome capture technique
make this new technique the preferred method for rese-
quencing P. vivax field isolates. In addition, studies are
on going to expand this technique to whole blood stored
on filter paper, which will completely remove the need
for a field laboratory thus reducing the technical chal-
lenges of collecting P. vivax field samples even further.
Methods
Ethics statement
The protocol used to collect human blood samples for
this work was approved by the Human Subjects Protec-
tion Program of The Scripps Research Institute and the
University of California, San Diego, and by the Ethical
Committees of Universidad Peruana Cayetano Heredia
and the Asociacion Benefica PRISMA, Iquitos, Peru.
Written informed consent was obtained from each sub-
ject or a parent in the case of minors. The consent form
states in English and Spanish that samples may be used
for any scientific purpose involving this or any other
project, now or in the future, and that the samples may
be shared with other researchers.
Sample collection
P. vivax DNA used in the whole genome capture proto-
col was isolated from symptomatic Peruvian malaria
patients blood smear positive for P. vivax malaria. Five
to ten mL of whole blood was obtained from each pa-
tient with informed consent before anti-malarials were
administered. Whole blood samples were centrifuged
and the serum and Buffy coat were removed. Erythro-
cytes were stored at −80 C. IQ07 was collected as
described previously and Acre3 was collected in the
identical manner [4]. Samples were collected in and
around Iquitos, Peru.
Isolation of genomic DNA
For samples SA96, SA97 and SA98, genomic DNA was
isolated from frozen whole blood samples using the
DNeasy Blood and Tissue kit (Qiagen) as per the manu-
facturers instructions. To test the feasibility of capture
from DNA isolated from filter paper, 125 ul of SA94 and
SA95 were added to Whatman FTA Nucleic Acid stor-
age cards. Cards were left at room temperature for 2–
3 weeks before nucleic acid extraction using the Gentra
Puregene blood kit (Qiagen).
Quantification of P. vivax DNA with qPCR
A Taqman qPCR assay was designed for both P. vivax b-
tubulin (PVX_094635) and P. vivax ATP-dependent
acyl-CoA synthetase (PVX_002785). Primers and probes
for each assay are listed in Table S1. The qPCR reaction
was conducted using Applied Biosystems Taqman 2x
Genotyping Master Mix (Life Technologies), 20 ng bulk
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genomic DNA, 900 nM of each primer, and 250 nM of
the fluorescent hydrolysis probe. Reactions were carried
out on an Applied Biosystems StepOne Plus (Life Tech-
nologies) using the manufacturers standard protocol.
Total P. vivax DNA was calculated by comparing the Ct
value of the sample to a 12-point standard curve of Sal1
reference DNA.
Creation of whole genome baits (WGB)
Whole genome amplified (Repli-g Kit, Qiagen) Sal1
reference genomic DNA was sheared to an average size
of 200 bp using an S-series Covaris Adaptive Focused
Acoustic machine (Covaris). Samples underwent end-
repair and dA-tailing (New England Biolabs) followed by
ligation of Illumina TruSeq v. 3-style Y-adaptors carrying
the T7 promoter sequence (Table S1). The T7 ligated li-
brary was run on a 2% agarose gel and a band corre-
sponding to 200 bp was cut and purified in 20 ul of TE
buffer with MinElute spin columns (Qiagen). Five ul of
purified library was then enriched with 14 cycles of PCR
using Phusion MasterMix HF (New England Biolabs)
(Table S1). Five pmoles of enriched library was used in a
20 ul in vitro transcription reaction following the manu-
facturers protocol (Ambion MEGAshortscript T7 Kit,
Life Technologies) with the exception that biotin labeled
dUTP was used in replacement of the supplied dUTP.
The reaction was purified with an RNeasy Mini column
(Qiagen) that included an on column DNase digestion.
A single in vitro transcription reaction provided a total
of 45 ug of Sal1 capture RNA.
Whole genome capture technique
Bulk genomic DNA was carried through the standard
Illumina library preparation process using Adaptive Fo-
cused Acoustics for shearing (Covaris), end-repair, A-
tailing and ligation (New England Biolabs). Hybridization
capture was carried out as previously described [6] with
two modifications: 2.5 ug of Human genomic DNA was
added in the initial blocking step and only 12 cycles of
post capture enrichment were performed. Briefly, 750 ng
of the whole genome baits were mixed with 20 units of
RNase inhibitor (SUPERase-In, Life Technologies),
heated for 2 min at 65 °C in a GeneAmp PCR System
9700 thermocycler (Applied Biosystems, Inc), and then
mixed with pre-warmed (65 °C) 2× hybridization buffer
(Agilent Technologies, Inc.). In a PCR plate, 500 ng of
each genomic DNA-fragment library was mixed with
2.5 μg of human Cot-1 DNA, 2.5 μg of salmon sperm
DNA, 2.5 ug of Human genomic DNA, and 1 unit of
blocking oligonucleotides complementary to the Illu-
mina TruSeq v. 3 adaptor, heated for 5 minutes at 95 °C,
and held for 5 minutes at 65 °C in the thermocycler.
The mixture was then added to the capture probes, and
the solution hybridization was performed for 24 hours at
65 °C.
After the hybridization, the captured targets were
selected by pulling down the biotinylated probe/target
hybrids by using streptavidin-coated magnetic beads
(Dynabeads MyOne Streptavidin T1, Life Technologies).
The magnetic beads were prepared by washing 3 times
and resuspending in binding buffer (1 M NaCl, 1 mM
EDTA, and 10 mM Tris–HCl, pH 7.5). The captured
target solution was then added to the beads and rotated
for 30 minutes at room temperature. The beads/captured
targets were then pulled down by using a magnetic separ-
ator, removing the supernatant, resuspending in pre-
warmed (65 °C) wash buffer (Agilent Technologies, Inc),
and then incubated for 15 minutes at room temperature.
The beads/captured probes were then pulled down with
the magnetic separator and washed by resuspension and
incubation for 10 minutes at 65 °C in wash buffer. After
three washes, elution buffer (0.1 M NaOH) was added and
incubated for 10 minutes at room temperature. The eluted
captured targets were then transferred to a tube contain-
ing neutralization buffer (1 M Tris–HCl, pH 7.5) and
desalted with Agencourt AMPure XP paramagnetic beads
(Beckman Coulter). Finally, the targets were enriched by
12-cycle PCR amplification by using 1 μl per sample as a
template, and the amplified targets were purified with
Agencourt AMPure XP beads.
Sequencing and data analysis
IQ07 was sequenced as described previously and Acre3
was sequenced in the identical manner [4]. For all of the
whole genome capture samples, genomic DNA libraries
were sequenced on an Illumina Hi-Seq2000 at the TSRI
Next Generation Sequencing Core Facility. Samples were
pair end sequenced for 101 bp per read and one 7 bp
index read using Illumina v. 3 chemistry. Base calls were
made using Illumina RTA (v. 1.12) software. Data for
each sample sequenced in this study is available in the
NCBI Sequence Read Archive [SRA: SRA047163.1].
Fastq files obtained from sequencing were aligned to
the Sal1 reference using BWA (v. 0.5.9) with soft clip-
ping of bases with quality score 2 and below [9]. Data
from the same sample library preparation sequenced in
different lanes was next merged into one file. PCR dupli-
cates were next identified and marked using Picard
(v. 1.51) MarkDuplicates. Aligned reads were then rea-
ligned around indels and areas of high entropy using
GATK (v. 1.0) IndelRealigner, and the base quality scores
of realigned reads were then recalibrated using GATK
TableRecalibration [10]. After realignment and recalibra-
tion the samples were considered “clean” and ready for
use in downstream analysis.
Genome wide coverage and loci covered to a certain per-
centage were calculated using GATK DepthOfCoverage
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[10]. For all GATK DepthOfCoverage analyses the mini-
mum mapping quality (mmq) was set to 29 and the mini-
mum base quality (mbq) was set to 20. For downsampling
analysis, only reads mapped in proper pairs were consid-
ered. These read pairs were filtered out from the total data
set using samtools view with the –f 2 option (v. 0.1.16) [12].
Downsampled data sets were created from the properly
mapped data sets using Picard DownsampleSam. For each
coverage threshold, five randomly downsampled data sets
were created and coverage was assessed using GATK
DepthOfCoverage. The average of the five technical repli-
cates was used to compare the percent of loci covered by
five or more reads between the leukocyte filtered sample
and whole genome capture sample.
SNVs were identified using GATK UnifiedGenotyper
with the options mbq 20, mmq 29, stand_emit_conf 10,
and stand_call_conf 50. Identified SNVs that contained
greater than 10% of reads mapping to the reference allele
were excluded as false positives. From a total of 125,789
raw SNVs identified across the five whole genome cap-
ture samples, 32,372 were retained in the high confi-
dence SNV data set that was used for further analysis.
Additional file
Additional file 1: Figure S1 and Figure S2. Normalized coverage by GC
% content. and comparison of depth of coverage of different %GC
regions on chromosome 10.
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